11. Myasthenia gravis Clinical trials / Disease details


Clinical trials : 315 Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02774239
(ClinicalTrials.gov)
October 201420/4/2015A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis ExacerbationMyasthenia GravisDrug: Human normal immunoglobulin G (IgG)University of AlbertaCSL BehringRecruiting18 Years80 YearsAll30Phase 3Canada
2EUCTR2012-001544-21-ES
(EUCTR)
07/11/201223/08/2012Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis.Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis. Myasthenia gravis
MedDRA version: 15.0;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: PRIVIGEN
Other descriptive name: IMMUNOGLOBULIN G
Vall d'Hebron Institut de Recerca (VHIR)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
84Spain